THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Robert Wild to Risk Factors

Back to Details
This is a "connection" page, showing publications Robert Wild has written about Risk Factors.
Robert Wild
Connection Strength
1.942
Risk Factors
  1. Hyperlipidemia and risk for preclampsia. J Clin Lipidol. 2022 May-Jun; 16(3):253-260.
    View in: PubMed
    Score: 0.132
  2. Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. Menopause. 2021 05 03; 28(6):610-618.
    View in: PubMed
    Score: 0.125
  3. Dyslipidemia in pregnancy. Cardiol Clin. 2015 May; 33(2):209-15.
    View in: PubMed
    Score: 0.083
  4. Women's Health Considerations for Lipid Management. Cardiol Clin. 2015 May; 33(2):217-31.
    View in: PubMed
    Score: 0.083
  5. Insights from the Women's Health Initiative: individualizing risk assessment for hormone therapy decisions. Semin Reprod Med. 2014 Nov; 32(6):433-7.
    View in: PubMed
    Score: 0.080
  6. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013 Mar; 20(3):254-60.
    View in: PubMed
    Score: 0.071
  7. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011 Mar 01; 95(3):1073-9.e1-11.
    View in: PubMed
    Score: 0.061
  8. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 May; 95(5):2038-49.
    View in: PubMed
    Score: 0.058
  9. Characterizing cardiovascular risk in women with polycystic ovary syndrome: more than the sum of its parts? Semin Reprod Med. 2009 Jul; 27(4):299-305.
    View in: PubMed
    Score: 0.055
  10. Endogenous androgens and cardiovascular risk. Menopause. 2007 Jul-Aug; 14(4):609-10.
    View in: PubMed
    Score: 0.048
  11. Options for hormone therapy in women who have had a hysterectomy. Menopause. 2007 May-Jun; 14(3 Pt 2):592-7; quiz 598-9.
    View in: PubMed
    Score: 0.047
  12. Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician. Clin Obstet Gynecol. 2007 Mar; 50(1):226-43.
    View in: PubMed
    Score: 0.047
  13. A relook at the relevance of thyroid stimulating hormone and thyroid autoimmunity for pregnancy outcomes: Analyses of randomized control trials data from Pregnancy in Polycystic Ovary Syndrome and Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation. Fertil Steril. 2025 May; 123(5):873-882.
    View in: PubMed
    Score: 0.040
  14. Intergenerational Occurrence of Premature Birth and Reproductive Health in Prematurely-Born Women in the Women's Health Initiative. Matern Child Health J. 2024 Oct; 28(10):1793-1811.
    View in: PubMed
    Score: 0.039
  15. The effect of improved metabolic syndrome parameters on live birth. Fertil Steril. 2024 Aug; 122(2):373-375.
    View in: PubMed
    Score: 0.038
  16. Healthy Lifestyle Index and Risk of Cardiovascular Disease Among Postmenopausal Women With Normal Body Mass Index. J Am Heart Assoc. 2023 06 20; 12(12):e029111.
    View in: PubMed
    Score: 0.036
  17. Association of Preterm Birth With Prevalent and Incident Hypertension, Early-Onset Hypertension, and Cardiovascular Disease in the Women's Health Initiative. Am J Cardiol. 2023 04 01; 192:132-138.
    View in: PubMed
    Score: 0.035
  18. The severity of individual menopausal symptoms, cardiovascular disease, and all-cause mortality in the Women's Health Initiative Observational Cohort. Menopause. 2022 Dec 01; 29(12):1365-1374.
    View in: PubMed
    Score: 0.035
  19. Association of infertility with atherosclerotic cardiovascular disease among postmenopausal participants in the Women's Health Initiative. Fertil Steril. 2022 05; 117(5):1038-1046.
    View in: PubMed
    Score: 0.033
  20. A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence. Fertil Steril. 2022 02; 117(2):408-418.
    View in: PubMed
    Score: 0.033
  21. Adiposity and breast, endometrial, and colorectal cancer risk in postmenopausal women: Quantification of the mediating effects of leptin, C-reactive protein, fasting insulin, and estradiol. Cancer Med. 2022 02; 11(4):1145-1159.
    View in: PubMed
    Score: 0.033
  22. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol. 2002 Jan; 186(1):35-43.
    View in: PubMed
    Score: 0.033
  23. Body Fat Distribution, Cardiometabolic Traits, and Risk of Major Lower-Extremity Arterial Disease in Postmenopausal Women. Diabetes Care. 2022 01 01; 45(1):222-231.
    View in: PubMed
    Score: 0.033
  24. Adverse Pregnancy Outcomes and Incident Heart Failure in the Women's Health Initiative. JAMA Netw Open. 2021 12 01; 4(12):e2138071.
    View in: PubMed
    Score: 0.033
  25. Recreational Physical Activity, Sitting, and Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev. 2022 01; 31(1):97-107.
    View in: PubMed
    Score: 0.032
  26. Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. Cancer. 2021 05 15; 127(10):1658-1667.
    View in: PubMed
    Score: 0.031
  27. The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative. Menopause. 2020 10; 27(10):1117-1125.
    View in: PubMed
    Score: 0.030
  28. Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative. J Vasc Surg. 2021 04; 73(4):1245-1252.e3.
    View in: PubMed
    Score: 0.030
  29. Feasibility and Utility of a Cardiovascular Risk Screening Tool in Women Undergoing Routine Gynecology Evaluation. J Womens Health (Larchmt). 2020 09; 29(9):1150-1159.
    View in: PubMed
    Score: 0.030
  30. It's Absolutely Relative: The Effect of Age on the BMI-Mortality Relationship in Postmenopausal Women. Obesity (Silver Spring). 2020 01; 28(1):171-177.
    View in: PubMed
    Score: 0.028
  31. The Effects of Reverse Causality and Selective Attrition on the Relationship Between Body Mass Index and Mortality in Postmenopausal Women. Am J Epidemiol. 2019 10 01; 188(10):1838-1848.
    View in: PubMed
    Score: 0.028
  32. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J. 2019 09 07; 40(34):2849-2855.
    View in: PubMed
    Score: 0.028
  33. Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population. Fertil Steril. 2019 06; 111(6):1129-1134.
    View in: PubMed
    Score: 0.027
  34. Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study. Cancer Causes Control. 2019 Apr; 30(4):355-363.
    View in: PubMed
    Score: 0.027
  35. Risk factors: assessment and preventive measures. Clin Obstet Gynecol. 1998 Dec; 41(4):966-75.
    View in: PubMed
    Score: 0.026
  36. Lipids and Women's Health: Recent Updates and Implications for Practice. J Womens Health (Larchmt). 2019 06; 28(6):752-760.
    View in: PubMed
    Score: 0.026
  37. Metabolic aspects of polycystic ovary syndrome. Semin Reprod Endocrinol. 1997 May; 15(2):105-10.
    View in: PubMed
    Score: 0.024
  38. Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility. Fertil Steril. 2017 Mar; 107(3):756-762.e3.
    View in: PubMed
    Score: 0.023
  39. Hormone replacement: effects on atherogenesis. Semin Reprod Endocrinol. 1996 Feb; 14(1):63-9.
    View in: PubMed
    Score: 0.022
  40. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015 Mar-Apr; 9(2):129-69.
    View in: PubMed
    Score: 0.021
  41. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med. 1995 Jan 16; 98(1A):27S-32S.
    View in: PubMed
    Score: 0.020
  42. The gynecologist and the prevention of cardiovascular disease. Am J Obstet Gynecol. 1995 Jan; 172(1 Pt 1):1-13.
    View in: PubMed
    Score: 0.020
  43. The gynecologist and cardiovascular disease: a window of opportunity for prevention. J Soc Gynecol Investig. 1994 Apr-Jun; 1(2):107-17.
    View in: PubMed
    Score: 0.019
  44. Matriarchal model for cardiovascular prevention. Obstet Gynecol Surv. 1994 Feb; 49(2):147-52.
    View in: PubMed
    Score: 0.019
  45. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012 Jan; 97(1):28-38.e25.
    View in: PubMed
    Score: 0.016
  46. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012 Mar-Apr; 18(2):112-26.
    View in: PubMed
    Score: 0.016
  47. Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. Clin Endocrinol (Oxf). 2011 Jan; 74(1):89-96.
    View in: PubMed
    Score: 0.015
  48. Maternal diabetes and renal agenesis/dysgenesis. Birth Defects Res A Clin Mol Teratol. 2010 Sep; 88(9):722-7.
    View in: PubMed
    Score: 0.015
  49. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril. 1990 Aug; 54(2):255-9.
    View in: PubMed
    Score: 0.015
  50. Hysterectomy prevalence and cardiovascular disease risk factors in American Indian women. Maturitas. 2005 Nov-Dec; 52(3-4):328-36.
    View in: PubMed
    Score: 0.010
  51. Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic american Indian women: the strong heart study. J Womens Health (Larchmt). 2004 Mar; 13(2):155-63.
    View in: PubMed
    Score: 0.010
  52. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study. Diabetes Care. 2002 Mar; 25(3):500-4.
    View in: PubMed
    Score: 0.008
  53. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000 Jan; 85(1):214-8.
    View in: PubMed
    Score: 0.007
  54. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998 May 13; 279(18):1445-51.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES